Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Homa Najafi"'
Autor:
Sepideh Abdi, Negar Taheri, Fatemeh Zahedi Haghighi, Mahya Khaki, Homa Najafi, Mohammad Mehdi Hemmati Komasi, Behrooz Hassani
Publikováno v:
Journal of Cardiovascular and Thoracic Research, Vol 15, Iss 2, Pp 86-92 (2023)
Introduction: Cardiac complications are the leading cause of death in thalassemia patients. It is assumed that progressive iron accumulation results in myocyte damage. Myocardial T2* measurement by cardiac MRI quantifies iron overload. We aimed to st
Externí odkaz:
https://doaj.org/article/fc3047626dc04ffa8cd3e9d11506e0cd
Autor:
Mahya Khaki, Parastoo Dehghan, Naghmeh Malekzadeh, Mohsen Khamoushi, Fahimehalsadat Shojaei, Sahar Memar Motazerin, Homa Najafi, Reza Boostani, Gholamreza Malekzadeh, Gerald Chi
Publikováno v:
Journal of Research in Clinical Medicine, Vol 9, Iss 1, Pp 34-34 (2021)
Background: The World Health Organization (WHO) declared a pandemic in March 2020 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Given the neurotropism feature of the coronavirus and growing number of COVID-19 associated neur
Externí odkaz:
https://doaj.org/article/b47026801a324e5d98717ec210ba1501
Publikováno v:
Coronary Artery Disease. 33:566-573
The risk of recurrent spontaneous coronary artery dissection (SCAD) is a major concern to SCAD patients and clinicians. Identifying the high-risk subsets of recurrent SCAD remains an ongoing challenge. The meta-analysis aimed to assess the potential
Autor:
Sahar Memar Montazerin, Jane J. Lee, Homa Najafi, Fahimehalsadat Shojaei, Jolanta Marszalek, Ali Seifi, Roghayeh Marandi, Gerald Chi
Publikováno v:
Neurocritical Care. 36:650-661
Several studies have demonstrated the usefulness of cardiac troponin I (cTn) levels in predicting adverse clinical outcomes of patients with anerusmal subarachnoid hemorrhage (aSAH). However, it remains unclear whether cTn levels can be a useful fact
Autor:
Nahid Rezaeian, Leila Hosseini, Negar Omidi, Mahya Khaki, Homa Najafi, Kianoosh Kasani, Mostafa Mousavizadeh, Yasaman Khalili, Mohammad Komasi, Yaser Toloueitabar, Sanaz Asadian
Purpose: Left ventricular (LV) replacement fibrosis is a marker of adverse cardiac events in hypertrophic cardiomyopathy (HCM). We aimed to assess the efficacy of the feature-tracking cardiac magnetic resonance (FT-CMR) in the detection of LV replace
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03d0bcb6ad45a76720e9d3da907b0b3b
https://ruj.uj.edu.pl/xmlui/handle/item/292785
https://ruj.uj.edu.pl/xmlui/handle/item/292785
Autor:
Fahimehalsadat Shojaei, Gerald Chi, Sahar Memar Montazerin, Homa Najafi, Jane J. Lee, Jolanta Marszalek, Firas Kaddouh, Ali Seifi
Publikováno v:
Clinical neurology and neurosurgery. 212
Efficacy and safety of pharmacologic thromboprophylaxis after an episode of intracerebral hemorrhage remains unclear. This meta-analysis aimed at comparing the clinical outcomes of intracerebral hemorrhage patients with or without pharmacologic throm
Autor:
Gerald Chi, Vamsikrishna Gunnam, Farima Kahe, S. Dahal, Homa Najafi, Jolanta Marszalek, Sahar Memar Montazerin, Adeel Jamil, Fahimehalsadat Shojaei, Jane J. Lee, Umer Jamil
Publikováno v:
Circulation. 142
Introduction: Preliminary evidence indicates that prophylactic-dosing thromboprophylaxis may be inadequate to control the increased risk of venous thromboembolism (VTE) in coronavirus disease 2019 (COVID-19) patients, and the usefulness of D-dimer me
Autor:
Jolanta Marszalek, Sahar Memar Montazerin, Adeel Jamil, Gerald Chi, Jane J. Lee, Homa Najafi, Fahimehalsadat Shojaei, Vamsikrishna Gunnam
Publikováno v:
Journal of Clinical Medicine
Volume 9
Issue 8
Journal of Clinical Medicine, Vol 9, Iss 2489, p 2489 (2020)
Volume 9
Issue 8
Journal of Clinical Medicine, Vol 9, Iss 2489, p 2489 (2020)
Background: Preliminary evidence indicates that prophylactic-dose thromboprophylaxis may be inadequate to control the increased risk of venous thromboembolism (VTE) in patients hospitalized for coronavirus disease 2019 (COVID-19) infection. Additiona
Publikováno v:
Critical pathways in cardiology. 19(3)
Cardiovascular disease marks the leading cause of mortality and morbidity in the United States. Pharmacological therapies have been developed to reduce the burden of cardiovascular diseases in the setting of large-scale randomized controlled trials.
Autor:
Gholam Reza Malekzadeh, Homa Najafi, Reza Boostani, Parastoo Dehghan, Fahimehalsadat Shojaei, Sahar Memar Motazerin, Naghmeh Malekzadeh, Mohsen Khamoushi, Gerald Chi, Mahya Khaki
Publikováno v:
Journal of Research in Clinical Medicine, Vol 9, Iss 1, Pp 34-34 (2021)
Background: The World Health Organization (WHO) declared a pandemic in March 2020 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Given the neurotropism feature of the coronavirus and growing number of COVID-19 associated neur